Skip to main content

Day: January 18, 2022

Resverlogix Announces Commencement of Patient Enrollment and Dosing in a Phase 2b Trial for a Promising Canadian-Developed COVID-19 Treatment

Resverlogix commences dosing of patients in Phase 2b COVID-19 studyPatients have received their first dose of apabetaloneCALGARY, Alberta, Jan. 18, 2022 (GLOBE NEWSWIRE) — Resverlogix Corp. (“Resverlogix”) (TSX:RVX) is pleased to announce today that enrollment and dosing of patients has commenced in a Phase 2b study at a site at the University of Alberta Hospital in Edmonton. The trial will evaluate the safety and efficacy of apabetalone as a potential oral treatment for COVID-19. Apabetalone’s unique dual epigenetic mechanism may help stop disease progression by regulating the expression of disease and inflammation causing genes, without altering DNA. Through this mechanism, apabetalone has the potential to address both the viral and the more deadly inflammatory aspects of COVID-19. “Today is a landmark...

Continue reading

Transocean Enabler Selected to Drill Injection Well and Sidetrack for Northern Lights Carbon Transport and Storage Project

STEINHAUSEN, Switzerland, Jan. 18, 2022 (GLOBE NEWSWIRE) — Transocean Ltd. (NYSE: RIG) announced today that, later this year as part of its current drilling contract with Equinor, the Transocean Enabler will drill one carbon injection well and a sidetrack for another carbon injection well drilled early 2020 in support of the Northern Lights Carbon Capture Storage Project, a joint venture created by Equinor, Shell and TotalEnergies. The project sets out to mitigate emissions and remove carbon dioxide from the atmosphere by creating the first cross-border, open-source carbon dioxide transport and storage infrastructure network in the European Union. “We are proud to participate in this important carbon capture and storage project in support of the EU’s energy policy and climate objectives,” said Janelle Daniel, Transocean’s Vice...

Continue reading

Kraig Biocraft Laboratories Prepares to Ship Finished Dragon Silk Yarn From Vietnam Factory

ANN ARBOR, Mich., Jan. 18, 2022 (GLOBE NEWSWIRE) — Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, announces it has completed production of the first Dragon Silk yarn produced entirely in Vietnam. The finished recombinant spider silk yarn was spun from raw spider silk produced at Prodigy Textiles, the Company’s subsidiary located in Quang Nam province, Vietnam. Today’s announcement marks a significant milestone for Kraig Labs, Prodigy Textiles, and the large-scale production of recombinant spider silk. This production run of Dragon Silk exhibits Prodigy Textiles’ full integration into Vietnam’s substantial silk textile industry. Vietnam produced nearly 1,000 metric...

Continue reading

Gilat to Report Fourth Quarter and Full Year 2021 Results on February 15th

PETAH TIKVA, Israel, Jan. 18, 2022 (GLOBE NEWSWIRE) — Gilat Satellite Networks Ltd. (Nasdaq: GILT, TASE: GILT), a worldwide leader in satellite networking technology, solutions, and services, today announced that it will release its fourth quarter and full year 2021 financial results on Tuesday, February 15, 2022. Conference Call and WebcastFollowing the release, Adi Sfadia, Chief Executive Officer, and Gil Benyamini, Chief Financial Officer, will discuss Gilat’s fourth quarter and full year 2021 results and business achievements and participate in a question and answer session: Date: Tuesday, February 15, 2022Start: 09:30 AM EST / 16:30 ISTDial-in:  US: 1-866-744-5399  International: +972-3-918-0610A simultaneous webcast of the conference call will be available on the Gilat website at www.gilat.com and through...

Continue reading

ADMA BioCenters Receives FDA Approval for its Fourth Plasma Collection Center Located in Goose Creek, SC

FDA approval positions Company to meet or exceed target of ten or more FDA-licensed plasma collection centers by year-end 2023 RAMSEY, N.J. and BOCA RATON, Fla. and GOOSE CREEK, S.C., Jan. 18, 2022 (GLOBE NEWSWIRE) — ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that it has received U.S. Food and Drug Administration (“FDA”) approval for its fourth ADMA BioCenters plasma collection facility located in Goose Creek, South Carolina. In conjunction, the facility was issued a compliance certification from the International Quality Plasma Program (“IQPP”), confirming the center meets facility and donor criteria for IQPP Certification. This plasma collection facility commenced operations...

Continue reading

Red White & Bloom Receives Full Licensing, Commences Operation of 15,000 Sq. Ft. Michigan Cannabis Manufacturing/Processing Facility

Platinum Vape branded productsRed White and Bloom will immediately commence operation of its new Warren facility as the hub for production and distribution for its wildly popular Platinum Vape® brand vapes, and will soon add gummies and chocolates for Michigan’s $1.8 billion medical and adult-use markets.Warren facility to become RWB’s central cannabis manufacturing, processing and distribution hub in Michigan, enabling distribution of RWB products to Michigan’s 400+ dispensaries — a $1.8 billion market where Platinum Vape™ was named a Biggest Brand by LeafLink and the #1 brand vape in Michigan by ArcView. 15,000 sq. ft. fully built-out facility, with the latest edibles production equipment already installed, allows RWB to launch chocolates and gummies alongside Platinum Vape via the same distribution channel. First...

Continue reading

Balchem Corporation Named on Newsweek’s 2022 List of America’s Most Responsible Companies

NEW HAMPTON, N.Y., Jan. 18, 2022 (GLOBE NEWSWIRE) —  Balchem Corporation (NASDAQ: BCPC) today announced that the Company has been named one of America’s Most Responsible Companies by Newsweek magazine. Balchem has earned a ranking amongst this prestigious list of companies for the second consecutive year. The list of America’s Most Responsible Companies, compiled by Newsweek in partnership with Statista Inc., is based on publicly available environmental, social and governance data as well as an independent survey of U.S. residents. This list recognizes the most responsible companies in the U.S. across a variety of industries. “Being recognized as one of America’s Most Responsible Companies is a great honor for Balchem and is a testament of our commitment and continued efforts to advance our Environmental, Social, and Governance...

Continue reading

Amryt Announces New Patents for Oleogel-S10

Amryt Announces New Patents for Oleogel-S10  DUBLIN, Ireland, and Boston MA, January 18, 2022 Amryt (Nasdaq: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializing novel treatments for rare diseases, announces an update regarding the patents for its lead development candidate, Oleogel-S10. Oleogel-S10 The United States Patent and Trademark Office (“USPTO”) has issued to Amryt a notice of allowance for US Patent Application No. 17/393,171 ‘Betulin-Containing Birch Bark Extracts and their Formulation’ with claims covering the Oleogel-S10 formulation. If Oleogel-S10 is approved by the FDA, the resulting patent will be listable in the Approved Drug Products with Therapeutic Equivalence Evaluations (commonly known as the Orange Book), published by the United States Food and Drug Administration...

Continue reading

Else Establishes Its Own Manufacturing Capacity in Oregon U.S.A.

BuckwheatBuckwheatVANCOUVER, British Columbia, Jan. 18, 2022 (GLOBE NEWSWIRE) — ELSE NUTRITION HOLDINGS INC. (BABY.V) (BABYF) (0YL.F) (“Else” or the “Company”) the Plant-Based baby, toddler and children nutrition company, today announced that is has signed an agreement to establish a specialized manufacturing site to process and prepare Else’s proprietary specialized, demineralized buckwheat for its infant formula. The Company completed the development of its unique production process for the demineralized buckwheat and anticipates producing the first batch of specially processed buckwheat in Q1 2022. The new facility output will support the infant formula production expected during the first years. The buckwheat will be processed under the strictest quality controls and standards without...

Continue reading

Northside Healthcare System in Atlanta Advances Surgical Robotics Program with Multi-System, Multi-Hospital Agreement for PROCEPT BioRobotics AquaBeam Systems

First and only image-guided, heat-free surgical robotic procedure aims to establish a new standard of care for patients with enlarged prostates REDWOOD CITY, Calif., Jan. 18, 2022 (GLOBE NEWSWIRE) — PROCEPT BioRobotics Corporation (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it now has five AquaBeam Robotic Systems installed across all of Northside Health Systems’ state-of-the-art surgical facilities. “I am thrilled that Northside is expanding their top-ranked surgical robotics program to now include Aquablation therapy at all five of their hospitals,” stated Lewis S. Kriteman, M.D., F.A.C.S. partner at Georgia Urology. “As the first surgeon in Georgia to perform Aquablation therapy, I applaud and thank Northside for leading the...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.